cetuximab + envolimab + mFOLFOX6

This is a combination regimen consisting of three main components: **cetuximab**, **envolimab**, and **mFOLFOX6**. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), commonly used in the treatment of colorectal and head and neck cancers. mFOLFOX6 is a chemotherapy regimen including **oxaliplatin**, **leucovorin (folinic acid)**, and **5-fluorouracil**, widely used as standard therapy in gastrointestinal malignancies, especially colorectal cancer[2][4][5][6][7]. Envolimab appears to be a monoclonal antibody (presumed anti–PD-L1), though it is not widely referenced in clinical literature as of this date and may represent an investigational PD-L1 inhibitor. This combination regimen would therefore represent a protocol combining targeted EGFR blockade (cetuximab), immune checkpoint inhibition (envolimab), and cytotoxic chemotherapy (mFOLFOX6) for synergistic anti-tumor activity.